Berber Piet
Nijmegen, GE, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery Protocol.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 07, 2026
Pre-treatment T cell phospho-signalling identifies clinical pembrolizumab response in non-small cell lung cancer patients.
Journal: International immunopharmacology
Published: March 02, 2026
Dosing, duration, and timing controversies in determining immune checkpoint inhibitor dosing regimens.
Journal: NPJ precision oncology
Published: August 07, 2025
No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects.
Journal: International journal of cancer
Published: June 05, 2025
[89Zr]Zr-DFO-avelumab accumulation in resectable non-small cell lung carcinoma indicates a suppressive tumor microenvironment amendable to neoadjuvant avelumab treatment.
Journal: Immunotherapy advances
Published: May 08, 2025
Early pembrolizumab clearance as prognostic biomarker for non-response in patients with advanced non-small cell lung cancer.
Journal: International journal of cancer
Published: April 24, 2025
Ex vivo pembrolizumab pharmacology for personalized PD-1 inhibitor therapy reveals a critical gap between receptor occupancy and T cell functionality.
Journal: International immunopharmacology
Published: March 04, 2025
Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment.
Journal: Clinical pharmacology and therapeutics
Published: February 03, 2025
Very Early Health Technology Assessment for Potential Predictive Biomarkers in the Treatment of Advanced Non-Small Cell Lung Cancer.
Journal: PharmacoEconomics - open
Published: January 05, 2025
A Case of a Large Brain Metastasis: Time for Multidisciplinary Consultation.
Journal: Cureus
Published: November 24, 2024
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 21, 2024
Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method to quantify the small molecule inhibitors adagrasib, alectinib, brigatinib, capmatinib, crizotinib, lorlatinib, selpercatinib, and sotorasib in human plasma.
Journal: Biomedical chromatography : BMC
Published: May 27, 2024
Last Updated: 09/26/2026